Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units

Table 2 Mixed effects, generalised linear model for ICU survival matched for propensity for use of ‘enhanced’ prophylaxis. Effect sizes are unscaled log odds (positive indicates survival benefit)

Term	Effect size (log odds)	p-value	95% CI
(Intercept)	0.38	0.37	− 0.452	1.21
Use of ‘enhanced’ (therapeutic) prophylaxis	0.64	0.0069	0.176	1.1
Age (years)	− 12.1	< 0.0001	− 15.6	− 8.69
BMI	− 1.34	0.02	− 2.46	− 0.211
History of hypertension	− 0.0204	0.94	− 0.53	0.489
History of diabetes	− 0.07	0.83	− 0.70	0.563
History of renal disease	− 0.951	0.1	− 2.1	0.198
Intubated	2.28	0.00026	1.1	3.5
D-dimer at ICU_admission	− 3390	0.38	− 11,000	4180
P/F ratio at ICU admission	18.4	0.13	− 5.24	42
CRP at ICU admission	− 19.8	0.26	− 54.3	14.7
Fibrinogen_at ICU_admission	− 5.14	0.9	− 89.8	79.5
Platelet count at_ICU_admission	61.5	0.0004	27.7	95.4
WBC at ICU admission	− 1.73	0.052	− 3.46	0.0119
Antiplatelet agent use	0.44	0.2	− 0.238	1.12

BMI, body mass index; ICU, intensive care unit; P/F partial pressure of oxygen/inspired fraction of oxygen; CRP, C-reactive protein; WBC, white blood cells

ISSN: 1364-8535